Eu, Eisai and Biogen
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
GlobalData on MSN7d
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed successMSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback